Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C90581
http://purl.obolibrary.org/obo/NCIT_C90581
|
|---|---|
| Preferred Name | Akt Inhibitor MK2206 |
| Definitions |
An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. |
|---|---|
| prefLabel | Akt Inhibitor MK2206
|
| label | Akt Inhibitor MK2206
|
| PDQ_Closed_Trial_Search_ID | 596332
|
| code | C90581
|
| Has_Target | |
| prefixIRI | NCIT:C90581
|
| in_subset |
See more
See less
|
| Display_Name | Akt Inhibitor MK2206
|
| Preferred_Name | Akt Inhibitor MK2206
|
| FDA_UNII_Code | 51HZG6MP1K
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Akt Inhibitor MK2206
|
| CAS_Registry | 1032349-93-1
|
| NCI_Drug_Dictionary_ID | 596332
|
| type | |
| ALT_DEFINITION | An orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor MK2206 binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 596332
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2933427
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |